Applied BioMath
Applied BioMath provides Quantitative Systems Pharmacology modeling and simulation services that predict clinical outcomes and optimize dosing for novel therapeutics. Now part of Certara, it serves biotech, pharma, and CRO clients across oncology, immunology, and rare diseases.
- Company typePrivate
- Founded2013
- HeadquartersConcord, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Applied BioMath does
Applied BioMath was founded in 2013 and headquartered in Concord, Massachusetts as a specialized computational modeling and simulation services firm focused on Quantitative Systems Pharmacology (QSP) for drug development. The company built mechanistic pharmacokinetic/pharmacodynamic models and simulation platforms designed to predict clinical outcomes, optimize dosing regimens, and de-risk therapeutic development for novel targets and modalities. Its primary scientific offering was an Immunocytokine Simulation Platform developed under NIH grant funding, targeting dose and therapeutic window prediction for a challenging modality class. The company served biotech, large pharma, and CRO clients, with named engagements including CDR-Life (T cell engager CDR404) and Sanofi (Virtual Twin model for infantile-onset Pompe disease).
Applied BioMath operated primarily as a professional services firm with bespoke QSP consulting engagements, supplemented by NIH and grant-based research funding. The company's go-to-market was sales-led and relationship-driven, anchored by deep scientific expertise in modeling for bispecific antibodies, ADCs, cell and gene therapies, and other complex biologics. Pricing was quote-based and not publicly disclosed, with engagements structured around tailored modeling deliverables rather than standardized software licenses.
In December 2023, Applied BioMath was acquired by Certara (NASDAQ: CERT), a public biosimulation company with 1,550+ employees across 30+ countries and a portfolio of regulatory-grade software platforms including Simcyp, Phoenix, Pinnacle 21, and Certara IQ. Following the acquisition, Applied BioMath's team and capabilities were integrated into Certara's QSP Center of Excellence, where the combined practice now serves 275+ clients globally with 70+ QSP scientists holding 300+ combined years of domain experience and a track record of 700+ completed projects. The combined entity maintains 30-32% adjusted EBITDA margins, invests in AI-enabled QSP software (Certara IQ), and pursues regulatory-tailwind opportunities such as Non-Animal Navigator aligned with the FDA's directive to reduce animal testing.
Applied BioMath firmographics
Firmographics- Name
- Applied BioMath
- Website
- https://appliedbiomath.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Applied BioMath provides Quantitative Systems Pharmacology modeling and simulation services that predict clinical outcomes and optimize dosing for novel therapeutics. Now part of Certara, it serves biotech, pharma, and CRO clients across oncology, immunology, and rare diseases.
- Ownership category
- akta.pro rank
Applied BioMath industry classification
Industry- Product category
- Quantitative Systems Pharmacology Consulting
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Applied BioMath is headquartered
LocationHeadquarters
- HQ city
- Concord
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Applied BioMath business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- QSP Consulting Services: Bespoke consulting engagements where Certara's team of 70+ QSP scientists provide tailored modeling and simulation services across oncology, immunology, neuroscience, rare diseases and other therapeutic areas. Engagements support target prioritization, dose determination, efficacy/toxicity assessment, and competitive evaluation.
- Software Licensing and Subscriptions: SaaS and on-premise licensing of software platforms including Certara IQ (AI-enabled QSP), Simcyp (PBPK modeling), Phoenix (PK/PD analysis), Pinnacle 21 (data standardization), D360 (scientific informatics), and others. Revenue is generated through annual subscriptions and software licenses.
- Platform and Software Offerings: Certara maintains a 30-32% adjusted EBITDA margin while investing in R&D, with plans to launch three new software offerings in Q4 2025 including AI-enabled Certara IQ for the QSP market.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise software licensing with consulting services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Applied BioMath product offering
Product offeringCore offering
Applied BioMath provides quantitative systems pharmacology (QSP) modeling and simulation services to biotechnology and pharmaceutical companies, using computational modeling combined with experimental data to predict clinical outcomes, optimize dosing, and de-risk drug development. The company also developed an Immunocytokine Simulation Platform under NIH grant funding for predicting optimal dose and therapeutic windows of immunocytokines. Following the December 2023 acquisition by Certara, Applied BioMath operates as part of Certara's QSP services division.
Product overview
Applied BioMath is a QSP (Quantitative Systems Pharmacology) consulting company specializing in computational modeling and simulation services for drug development. Their primary offering is a simulation platform developed under NIH funding for predicting optimal dose and therapeutic window of immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success.
Differentiator
Problem solved
Functional benefit
Products and services
- Immunocytokine Simulation Platform
- QSP Modeling and Simulation Services
Quantifiable outcome
- QSP-derived starting dose accepted for IND and CTA for CDR-Life's T cell engager CDR404, enabling higher starting dose in clinical trial
- +2 more outcomes
Companies that use Applied BioMath
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Applied BioMath technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Applied BioMath partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- SanoficoreSanofi collaborated with Certara (formerly Applied BioMath) to develop a QSP-based Virtual Twin model for Pompe disease, leveraging Certara's Virtual Twin technology to compare the effects of avalglucosidase alfa vs standard of care for infantile-onset Pompe disease (IOPD) patients. The model provides mechanism-based treatment insights into heterogeneous patient populations.
- National Institutes of Health (NIH)coreApplied BioMath was awarded a grant by the NIH to develop a simulation platform for predicting optimal dose and therapeutic window of Immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success. This grant was prior to the December 2023 acquisition by Certara.
- CDR-LifecoreCDR-Life engaged Certara's QSP team to support the development of CDR404, a T cell engager. Certara's QSP modeling and clinical pharmacology package was instrumental in enabling a higher first-in-human starting dose that was accepted for both IND and CTA. The collaboration is ongoing with plans to update the QSP model with real patient data.
- Leiden UniversityminorPiet van der Graaf, Senior Vice President and Head of QSP at Certara, holds a professorship of Systems Pharmacology at Leiden University, facilitating academic collaboration and research output in quantitative systems pharmacology.
- Cincinnati Children's Hospital Medical CenterminorPiet van der Graaf holds a professorship of Pediatrics at Cincinnati Children's Hospital Medical Center, supporting academic-industry collaboration in pediatric pharmacology and QSP modeling.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Applied BioMath competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Applied BioMath social profiles
Digital presenceApplied BioMath financial estimates
Financial estimateRevenue estimate
Valuation estimate
Applied BioMath leadership team
Management profileNumber of profiles
Applied BioMath funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Applied BioMath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Applied BioMath
What does Applied BioMath do?
Applied BioMath provides quantitative systems pharmacology (QSP) modeling and simulation services to biotechnology and pharmaceutical companies, using computational modeling combined with experimental data to predict clinical outcomes, optimize dosing, and de-risk drug development. The company also developed an Immunocytokine Simulation Platform under NIH grant funding for predicting optimal dose and therapeutic windows of immunocytokines. Following the December 2023 acquisition by Certara, Applied BioMath operates as part of Certara's QSP services division.
Is Applied BioMath a public or private company?
Applied BioMath is a private company. It is classified as corporate owned and is currently acquired.
When was Applied BioMath founded?
Applied BioMath was founded in 2013. It employs 11 to 50 people.
Where is Applied BioMath based?
Applied BioMath is headquartered in Concord, United States, in the North America region.
How does Applied BioMath make money?
Three revenue lines are on record. QSP Consulting Services are the primary driver. The others are software Licensing and Subscriptions and platform and Software Offerings.
Does Applied BioMath have an API?
No public API is recorded for Applied BioMath.
What industry is Applied BioMath in?
Applied BioMath's product category is Quantitative Systems Pharmacology Consulting. Its primary akta.pro industry code is HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.